Novocure Ltd (NASDAQ:NVCR) insider Yoram Palti sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, April 20th. The stock was sold at an average price of $11.24, for a total value of $89,920.00. Following the transaction, the insider now directly owns 127,825 shares in the company, valued at $1,436,753. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Yoram Palti also recently made the following trade(s):

  • On Monday, April 17th, Yoram Palti sold 4,000 shares of Novocure stock. The stock was sold at an average price of $10.77, for a total value of $43,080.00.
  • On Thursday, April 13th, Yoram Palti sold 4,000 shares of Novocure stock. The stock was sold at an average price of $10.43, for a total value of $41,720.00.
  • On Wednesday, April 12th, Yoram Palti sold 4,000 shares of Novocure stock. The stock was sold at an average price of $10.72, for a total value of $42,880.00.
  • On Tuesday, April 18th, Yoram Palti sold 16,000 shares of Novocure stock. The stock was sold at an average price of $10.64, for a total value of $170,240.00.

Shares of Novocure Ltd (NASDAQ:NVCR) traded down 0.87% during trading on Friday, hitting $11.45. The company’s stock had a trading volume of 739,782 shares. The company’s market capitalization is $996.97 million. The firm’s 50 day moving average is $8.68 and its 200-day moving average is $7.94. Novocure Ltd has a 1-year low of $5.95 and a 1-year high of $14.93.



Novocure (NASDAQ:NVCR) last released its quarterly earnings results on Thursday, February 23rd. The medical equipment provider reported ($0.26) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.13. Novocure had a negative return on equity of 69.89% and a negative net margin of 219.29%. The firm earned $30.20 million during the quarter, compared to analysts’ expectations of $26.95 million. Analysts forecast that Novocure Ltd will post ($0.91) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

TRADEMARK VIOLATION NOTICE: “Novocure Ltd (NVCR) Insider Yoram Palti Sells 8,000 Shares” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/04/21/novocure-ltd-nvcr-insider-yoram-palti-sells-8000-shares.html.

A number of large investors have recently added to or reduced their stakes in the stock. Creative Planning boosted its stake in Novocure by 32.1% in the first quarter. Creative Planning now owns 16,857 shares of the medical equipment provider’s stock worth $137,000 after buying an additional 4,100 shares in the last quarter. Peregrine Capital Management LLC boosted its stake in Novocure by 7.4% in the first quarter. Peregrine Capital Management LLC now owns 1,210,934 shares of the medical equipment provider’s stock worth $10,051,000 after buying an additional 83,448 shares in the last quarter. Macquarie Group Ltd. boosted its stake in Novocure by 18.4% in the fourth quarter. Macquarie Group Ltd. now owns 98,087 shares of the medical equipment provider’s stock worth $770,000 after buying an additional 15,218 shares in the last quarter. Teachers Advisors LLC boosted its stake in Novocure by 21.2% in the fourth quarter. Teachers Advisors LLC now owns 95,674 shares of the medical equipment provider’s stock worth $751,000 after buying an additional 16,741 shares in the last quarter. Finally, Flinton Capital Management LLC acquired a new stake in Novocure during the fourth quarter worth $111,000. 21.98% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently commented on the company. Zacks Investment Research raised Novocure from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Wednesday. Aegis reissued a “buy” rating and set a $14.00 price target on shares of Novocure in a research report on Tuesday. Wedbush reissued an “outperform” rating and set a $20.00 price target on shares of Novocure in a research report on Friday, April 7th. JMP Securities reissued an “outperform” rating and set a $34.00 price target on shares of Novocure in a research report on Tuesday, April 4th. Finally, JPMorgan Chase & Co. reissued a “buy” rating and set a $14.00 price target on shares of Novocure in a research report on Sunday, February 26th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Novocure presently has an average rating of “Buy” and a consensus target price of $17.00.

Novocure Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

5 Day Chart for NASDAQ:NVCR

Receive News & Stock Ratings for Novocure Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure Ltd and related stocks with our FREE daily email newsletter.